NCT06192576 - A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

January 2, 2029

Study Completion Date

January 15, 2029

Conditions

Niemann-Pick DiseasesAcid Sphingomyelinase Deficiency

Interventions

DRUG

Olipudase alfa

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.

Trial Locations (4)

RECRUITING

Pulse InfoFrame US Inc.- Site Number: 001001, Philadelphia

RECRUITING

Ann and Robert H Lurie Children's Hospital of Chicago- Site Number: 001002, Chicago

RECRUITING

Dell Children's Medical Center- Site Number : 1001-2, Austin

RECRUITING

Children's Hospital Medical Center- Site Number: 001003, Cincinnati